🇺🇸 FDA

Intelligence Platform

Patents

Browse 822 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11926670

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11903920

Cannabinoid formulation: production method and use

CHIROSYN DISCOVERY TECHNOLOGIES INC. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11904046

Hydrocortisone oral liquid formulations

Eton Pharmaceuticals, Inc. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11878074

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866743

Pharmaceutical formulations, methods for treating chemical warfare agent exposure, and mod

TELEDYNE FLIR DETECTION, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11865179

Progesterone formulations having a desirable PK profile

Compass Therapeutics LLC · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11851451

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and th

Compass Pathfinder Limited · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11850225

Baclofen formulations and methods of minimizing patient exposure to metabolite variations

AMNEAL PHARMACEUTICALS LLC · Granted Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844779

PKC-Delta-I inhibitor formulations and uses thereof

United States Government as represented by the Department of Veterans Affairs · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844805

Formulations of testosterone and methods of treatment therewith

The Board of Regents of the University of Texas System · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839594

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839623

Antiviral prodrugs and formulations thereof

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833157

Precipitation resistant small molecule drug formulations

XERIS PHARMACEUTICALS, INC. · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11819496

Topical roflumilast formulation having improved delivery and plasma half-life

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11813359

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11807868

Adeno-associated variants, formulations and methods for pulmonary delivery

4D MOLECULAR THERAPEUTICS INC. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806398

Citrate buffered VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806429

Film formulations containing dexmedetomidine and methods of producing them

BioXcel Therapeutics, Inc. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806400

Injectable ibuprofen formulation

Cumberland Pharmaceuticals Inc. · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11795180

Formulation of a pan-JAK inhibitor

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793819

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786518

Ophthalmic formulations and uses thereof

Aldeyra Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786598

Lipid formulations for delivery of therapeutic agents

ARBUTUS BIOPHARMA CORPORATION · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11759446

Liquid tasimelteon formulations and methods of use thereof

VANDA PHARMACEUTICALS INC. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted